NORWAY
Norway
Sweden Finland
Law and Practice Contributed by: Vebjørn Krag Iversen, Nora Bratheim, Kristin Erstad Remvik and Guro S. K. Nybø Wikborg Rein Advokatfirma AS
Oslo
Russia
Denmark
Contents 1. Life Sciences and Pharma/Biopharma Patent Litigation p.147 1.1 Claimants/Plaintiffs to an Action p.147 1.2 Defendants/Other Parties to an Action p.147 1.3 Preliminary Injunction Proceedings p.147 1.4 Structure of Main Proceedings on Infringement/ Validity p.148 1.5 Timing for Main Proceedings on Infringement/Validity p.148 1.6 Requirements to Bring Infringement Action p.148 1.7 Pre-Action Discovery/Disclosure p.148 1.8 Search and Seizure Orders p.148 1.9 Declaratory Relief p.149 1.10 Doctrine of Equivalents p.149 1.11 Clearing the Way p.149 1.12 Experts p.149
4. Patent Term Extensions for Pharmaceutical Products p.153 4.1 Supplementary Protection Certificates p.153 4.2 Paediatric Extensions p.153 4.3 Paediatric-Use Marketing Authorisations p.153 4.4 Orphan Medicines Extensions p.153 5. Relief Available for Patent Infringement p.153 5.1 Preliminary Injunctive Relief p.153 5.2 Final Injunctive Relief p.153 5.3 Discretion to Award Injunctive Relief (Final or Preliminary) p.153 5.4 Damages p.153 5.5 Legal Costs p.154 5.6 Relevance of Claimant/Plaintiff Conduct to Relief p.154 6. Other IP Rights p.154 6.1 Trade Marks p.154 6.2 Copyright p.154 6.3 Trade Secrets p.154 7. Appeal p.154 7.1 Timeframe to Appeal Decision p.154 7.2 Appeal Court(s) Arbiter p.155 7.3 Special Provisions p.155 8. Other Relevant Forums/Procedures p.155 8.1 The UPC or Other Forums p.155 9. Alternative Dispute Resolution p.155 9.1 ADR Options p.155 10. Settlement/Antitrust p.155 10.1 Considerations and Scrutiny p.155 11. Collective Redress p.156 11.1 Group Claims p.156
1.13 Use of Experiments p.149 1.14 Discovery/Disclosure p.149
1.15 Defences and Exceptions to Patent Infringement p.150 1.16 Stays and Relevance of Parallel Proceedings p.150 1.17 Patent Amendment p.150 1.18 Court Arbiter p.150 2. Generic Market Entry p.150 2.1 Infringing Acts p.150 2.2 Regulatory Data and Market Exclusivity p.151 2.3 Acceptable Pre-Launch Preparations p.151 2.4 Publicly Available Drug and Patent Information p.151 2.5 Reimbursement and Pricing/Linkage Markets p.152 3. Biosimilar Market Entry p.152 3.1 Infringing Acts p.152 3.2 Data and Regulatory Exclusivity p.152 3.3 Acceptable Pre-Launch Preparations p.152 3.4 Publicly Available Drug and Patent Information p.152 3.5 Reimbursement and Pricing/Linkage Markets p.152
145 CHAMBERS.COM
Powered by FlippingBook